NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
Clinical Trials
11 trialsNCT06305962 2026-02-19
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Phase EARLY_PHASE1 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT07389525 2026-02-05
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Indiana University
Phase EARLY_PHASE1 Not yet recruiting
NCT06472661 2025-11-20
Mel 70
University of Virginia
Phase EARLY_PHASE1 Recruiting
NCT03276832 2025-10-28
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT05704933 2025-10-20
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT05279027 2025-09-19
Zr89 + PET Companion Trial
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT06216938 2025-04-10
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
University of Pittsburgh
Phase EARLY_PHASE1 Recruiting